Fonadelpar (SJP‑0035) is an investigational ophthalmic drug developed as a peroxisome proliferator‑activated receptor delta (PPAR‑δ) agonist. It’s being studied mainly for treating dry eye disease and corneal epithelial disorders, with clinical trials reaching Phase III for dry eye and Phase II for corneal epithelial defects. By activating PPAR‑δ, fonadelpar may enhance lipid metabolism and reduce inflammation, promoting corneal wound healing and improved ocular surface function. The directory classifies it as a clinical API with a synthetic source/manufacturing origin. Other names for this substance include NPS-005 and SJP-0035. Its PubChem CID is 9827461.
Fonadelpar
| CAS No | 515138-06-4 |
|---|---|
| Molecular Formula | C25H23F3N2O4S |
| Molecular Weight | 504.50 g/mol |
| Synonyms | 2-[[5-methyl-3-[2-[4-propan-2-yl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]ethyl]-1,2-benzoxazol-6-yl]oxy]acetic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Fonadelpar (SJP‑0035) is an investigational ophthalmic drug developed as a peroxisome proliferator‑activated receptor delta (PPAR‑δ) agonist.
The listed CAS number is 515138-06-4.
The listed molecular formula is C25H23F3N2O4S.
The listed molecular weight is 504.50 g/mol.
2-[[5-methyl-3-[2-[4-propan-2-yl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]ethyl]-1,2-benzoxazol-6-yl]oxy]acetic acid.
The source lists NPS-005 and SJP-0035.